Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Oct. 1, 2014, 45 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $57.29 to $23,367,660.00.

Highlighted Stocks Traded by Insiders:

Moody's Corporation (MCO) - FREE Research Report

Duffie Darrell, who is Director at Moody's Corporation, sold 500 shares at $94.13 on Oct. 1, 2014. Following this transaction, the Director owned 21,864 shares meaning that the stake was reduced by 2.24% with the 500-share transaction.

The shares most recently traded at $92.72, down $1.41, or 1.52% since the insider transaction. Historical insider transactions for Moody's Corporation go as follows:

  • 4-Week # shares sold: 10,000
  • 12-Week # shares sold: 15,000
  • 24-Week # shares sold: 30,500

The average volume for Moody's Corporation has been 799,000 shares per day over the past 30 days. Moody's Corporation has a market cap of $20.0 billion and is part of the services sector and diversified services industry. Shares are up 18.02% year-to-date as of the close of trading on Wednesday.

Moody's Corporation provides credit ratings; and credit, capital markets, and economic related research, data, and analytical tools worldwide. The stock currently has a dividend yield of 1.18%. The company has a P/E ratio of 22.4. Currently, there are 4 analysts who rate Moody's Corporation a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MCO - FREE

TheStreet Quant Ratings rates Moody's Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, reasonable valuation levels, expanding profit margins and good cash flow from operations. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Moody's Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Eli Lilly and (LLY) - FREE Research Report

Lilly Endowment Inc, who is 10% Owner at Eli Lilly and, sold 200,000 shares at $65.07 on Oct. 1, 2014. Following this transaction, the 10% Owner owned 132.7 million shares meaning that the stake was reduced by 0.15% with the 200,000-share transaction.

The shares most recently traded at $64.90, down $0.17, or 0.26% since the insider transaction. Historical insider transactions for Eli Lilly and go as follows:

  • 4-Week # shares bought: 17,157
  • 4-Week # shares sold: 210,000
  • 12-Week # shares bought: 17,157
  • 12-Week # shares sold: 705,000
  • 24-Week # shares bought: 17,157
  • 24-Week # shares sold: 2.8 million

The average volume for Eli Lilly and has been 3.6 million shares per day over the past 30 days. Eli Lilly and has a market cap of $72.5 billion and is part of the health care sector and drugs industry. Shares are up 27.61% year-to-date as of the close of trading on Wednesday.

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates in two segments, Human Pharmaceutical Products and Animal Health Products. The stock currently has a dividend yield of 3%. The company has a P/E ratio of 20.7. Currently, there are 6 analysts who rate Eli Lilly and a buy, 1 analyst rates it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on LLY - FREE

TheStreet Quant Ratings rates Eli Lilly and as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Eli Lilly and Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Interactive Brokers Group (IBKR) - FREE Research Report

Galik Milan, who is SVP Software Development at Interactive Brokers Group, sold 1,800 shares at $25.00 on Oct. 1, 2014. Following this transaction, the SVP Software Development owned 712,217 shares meaning that the stake was reduced by 0.25% with the 1,800-share transaction.

The shares most recently traded at $25.06, up $0.05, or 0.22% since the insider transaction. Historical insider transactions for Interactive Brokers Group go as follows:

  • 4-Week # shares sold: 14,400
  • 12-Week # shares sold: 49,500
  • 24-Week # shares sold: 67,500

The average volume for Interactive Brokers Group has been 390,400 shares per day over the past 30 days. Interactive Brokers Group has a market cap of $1.4 billion and is part of the financial sector and financial services industry. Shares are up 2.51% year-to-date as of the close of trading on Wednesday.

Interactive Brokers Group, Inc. operates as an automated electronic broker and market maker. The stock currently has a dividend yield of 1.6%. The company has a P/E ratio of 25.5. Currently, there are 2 analysts who rate Interactive Brokers Group a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on IBKR - FREE

TheStreet Quant Ratings rates Interactive Brokers Group as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, compelling growth in net income, revenue growth, reasonable valuation levels and expanding profit margins. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Interactive Brokers Group Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null